European Biotech Acquisition Corp (EBAC) to Combine with Oculis SA in $218M Deal

Oct 17, 2022 Deal Announcements & Amendments, Headline Post, INTEL by Nicholas Alan Clayton

European Biotech (NASDAQ:EBAC) has entered into a definitive agreement to combine with biopharmaceutical firm Oculis at an enterprise value of $218 million. Lausanne, Switzerland-based Oculis is developing a range of therapies for eye diseases with the most advanced having entered Phase III trials. The combined company is expected to trade on the Nasdaq once the
Read More

To access this post, you must purchase a Monthly or Yearly SPACInsider Subscription, or log in if you're a member.

European Biotech Acquisition Corp (EBAC) to Combine with Oculis SA in $218M Deal

European Biotech Acquisition Corp (EBAC) to Combine with Oculis SA in $218M Deal

ByNicholas Alan Clayton